Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Merger or Acquisition (August 2020)
9 slides from Omnicell's merger presentation, Aug 12, 2020
Slide 1: Acquisition of 340B Link Business Expands Omnicell's Autonomous Pharmacy Portfolio
Acquisition of 340B Link Business Expands Omnicell’s Autonomous Pharmacy Portfolio August 12, 2020
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the consummation of the acquisition, the expected benefits of the acquisition of the 340B Link business, including on Omnicell’s non-GAAP ear
Slide 3: Compelling Strategic Benefits
Compelling Strategic Benefits Critical Inventory Management • Instrumental to compliance and financial Solution for Covered Entities health for many health systems Participating in the 340B Program • Supports central pharmacy inventory management and decision making • Attractive • Manages complex pr
Slide 4: 340B Link Business at a Glance
340B Link Business at a Glance Based in Plano, TX. Provides software-enabled Strong client focus, driving ~$1.4B Company Profile services to help Covered Entities manage their aggregate 340B savings and 95%+ 340B program while maintaining compliance retention rate annually and maximizing efficiency
Slide 5: Growing Market
Growing Market Covered Entity (CE) Sites Drug Purchases Under 340B Program (sites in thousands) $61.0 Purchases at discounted 340B prices increased from ~$9B in 2014 to almost $30B in 2019, Segment representing more than a 27% CAGR $46.3 CAGR: 17.4% ($ in billions) 38.4 $31.1 34.5 $33.7 29.7 $22.0 $
Slide 6: Directly Strengthens Key Autonomous Pharmacy Pillars
Directly Strengthens Key Autonomous Pharmacy Pillars Safety Financial Efficiency Compliance People 340B Link business extends Maximizes client savings Automates inventory Leading qualification Supports management access to patients with from all participating management and contract engine designed
Slide 7: 340B Link Complements Omnicell's Existing Solutions (Post-Close)
340B Link Complements Omnicell’s Existing Solutions (Post-Close) Technical Services Professional Services Advisory Services Outcomes Service Outcomes Omnicell One Safety Intelligence 340B Analysis Inventory Analytics Diversion Management Compliance Population Health + Financials 340B Link 340B + Ope
Slide 8: Transaction Overview
Transaction Overview Transaction $225 million in cash, subject to customary adjustments Consideration Sources of Cash on hand plus proceeds from Omnicell’s existing revolving credit facility Financing Earnings Impact High growth tech enabled services recurring revenue business with attractive return
Slide 9: Slide 9